Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

Jan 9 2010

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference, taking place February 8-9 at the>

“This conference provides industry executives, clinical thought leaders and investment professionals the opportunity to discuss therapeutic areas of need and expectations for the next decade’s market environment.”

“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts – from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO. “This conference provides industry executives, clinical thought leaders and investment professionals the opportunity to discuss therapeutic areas of need and expectations for the next decade’s market environment.”

This year, BIO is collaborating with Panel Intelligence (formerly MedPanel), a healthcare market research firm, to identify key opinion leaders based on knowledge and expertise in their respective fields and affiliations with prestigious academic institutions and medical foundations.

The BIO CEO & Investor Conference’s therapeutic workshops will focus on topics addressing the latest developments in therapies for a wide range of diseases. This year’s therapeutic workshop topics include:

Sarcoma: Connecting the Dots on New Therapies
Monday, February 8^th, 9:00am-10:00am

• John G. Curd, M.D.; President and Chief Medical Officer, Threshold Pharmaceuticals
• Jonathan Lewis, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer, ZIOPHARM Oncology
• Robert G. Maki, M.D., Ph.D; Associate Member, Co-Leader, Adult Sarcoma Program, Memorial Sloan-Kettering Cancer Center

RNAi Based Technology: No Longer Single & Stranded
Monday, February 8, 12:30-1:35pm

• Simos Simeonidis, PhD; Managing Director, Rodman & Renshaw, LLC
• Noah D. Beerman, President and Chief Executive Officer, RXi Pharmaceuticals
• J. Michael French; Chief Executive Officer, MDRNA
• Alnylam Pharmaceuticals

Alzheimer’s Disease: A Panel to Remember
Tuesday, February 9^th, 9:00am-10:00am

• Tony Cruz, MD; Chief Executive Officer, Transition Therapeutics
• David Hung, MD; President & Chief Executive Officer, Medivation
• Carlos V. Paya, MD; PhD, President, Elan
• Alzheimer’s Association
• Steven Ferris, PhD; Friedman Professor and Director of Alzheimer’s Disease Center, Center of Excellence on Brain Agin, New York University Langone Medical Center

HCV: Liver Long & Prosper
Tuesday, February 9, 12:00pm-1:00pm

• M. Michelle Berrey, M.D., M.P.H.; Chief Medical Officer, Pharmasset
• Robert S. Kauffman, M.D., Ph.D, Chief Medical Officer and Senior Vice President Clinical Development
• Steve Worland, Ph.D.,; President & Chief Executive Officer, Anadys Pharmaceuticals
• Douglas T. Dieterich, M.D.; Professor of Medicine, Director of Outpatient Hepatology in the Division of Liver Diseases and Director of CME in the Department of Medicine, Mount Sinai School of Medicine

Lupus: New Care for Too Much Flare
Tuesday, February 9^th, 3:00pm-4:00pm

• Mark Schoenebaum, MD; Managing Director & Senior Biotechnology Analyst, Deutsche Bank
• Barry A. Labinger, Executive Vice President & Chief Commercial Officer, Human Genome Sciences
• Sandra C. Raymond, President and Chief Executive Officer, Lupus Foundation of America
• Richard Furie, M.D.; Chief of the Division of Rheumatology & Allergy-Clinical Immunology, North Shore-Long Island Jewish Health System